MusclePharm Corp
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $50.0M | $64.4M | $79.7M | $24.2M | $93.6M | $132.5M |
| Operating income | −$8.9M | $2.6M | −$15.1M | −$1.4M | −$6.6M | −$8.7M |
| Net income | −$12.9M | $3.2M | −$18.9M | −$2.5M | −$12.5M | −$3.5M |
| Total assets | $11.2M | $13.0M | $14.5M | $29.4M | $30.3M | $34.1M |
| Total liabilities | $43.4M | $37.4M | $42.5M | $49.6M | $47.2M | $39.0M |
| Equity | −$32.2M | −$24.4M | −$28.0M | −$20.2M | −$16.8M | −$4.9M |
| EPS (diluted) | $-0.39 | $0.07 | $-0.92 | — | — | — |
| Shares out. | 33.5M | 33.1M | 33.0M | 14.7M | 14.1M | 13.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −17.8%
- Net margin
- −25.7%
- Return on equity
- 40.0%
- Return on assets
- −114.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 387.2%
- Debt / equity
- —
- Book value / share
- $-0.96
- Revenue growth (YoY)
- −22.3%
- Net income growth (YoY)
- −504.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -83.51distress
- Accruals / assets
- −43.0%clean
- Beneish M-Score
- -4.14normal
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 17, 2022
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Qmissed a reporting deadline ↗May 16, 2019
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| White Winston Select Asset Fund Series Fund Mp-18, Llc10% owner | Mar 29, 2022 | Sell | 626,826 | $0.00 |
| White Winston Select Asset Fund Series Fund Mp-18, Llc10% owner | Sep 30, 2019 | Buy | 626,826 | $0.00 |
| White Winston Select Asset Fund Series Fund Mp-18, Llc10% owner | Sep 27, 2019 | Buy | 103,677 | $0.00 |
| Wynnefield Partners Small Cap Value Lp I10% owner | Sep 27, 2019 | Buy | 2,444 | $0.53 |
| Drexler Ryan CharlesOfficer — CEO | Jan 5, 2018 | J | 81,113 | $0.65 |
| Bush William JohnDirector | Jul 1, 2019 | Grant | 238,095 | $0.00 |
| Desmond John JDirector | Jul 1, 2019 | Grant | 357,143 | $0.00 |
| Wynnefield Partners Small Cap Value Lp I10% owner | Aug 19, 2019 | Buy | 4,900 | $0.40 |
| Wynnefield Partners Small Cap Value Lp I10% owner | Aug 14, 2019 | Buy | 5,400 | $0.41 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer changeAug 31, 2023
- Director / officer changeJul 19, 2023
- Director / officer changeMar 10, 2023
- Bankruptcy or receivershipJan 11, 2023
- Changed auditorJan 11, 2023
- Bankruptcy or receivershipJan 9, 2023
- Director / officer changeSep 29, 2022
- Debt acceleration / triggering eventSep 19, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.